Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin Infusion for Ventricular Infarction Limitation (BIVAL)
NCT02565147Phase 3Terminated
- Sponsor
- The Medicines Company
- Start
- Dec 2014
- Primary completion
- Jun 2016
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of bivalirudin in ST elevation myocardial infarction (STEMI), sponsored by The Medicines Company. Started Dec 2014; status: terminated.
02
Drugs
bivalirudin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02565147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565147.